Sociedad Americana de Hirudoterapia

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Case-control study published in Microsurgery (2014)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosPannucci CJ et al. · Microsurgery, 2014

Abstract

BACKGROUND: Free tissue transfer is an accepted method for breast reconstruction. Surgically uncorrectable venous congestion is a rare but real occurrence after these procedures. Here, we report our experience with the management of surgically uncorrectable venous congestion after free flap breast reconstruction using medicinal leech therapy. METHODS: We queried our prospectively maintained institutional database for all patients with venous congestion after free flap breast reconstruction since 2005. Chart review was performed for all patients having post-operative venous congestion. We compared patients with surgically correctable venous congestion and surgically uncorrectable venous congestion requiring medicinal leech therapy. RESULTS: Twenty-three patients had post-operative venous congestion, and four of these patients were surgically uncorrectable requiring medicinal leech therapy. Patients who required leech therapy had lower hemoglobin nadirs, received more blood transfusions, and received a higher number of total units of red blood cells than patients who did not require leech therapy. Among four patients who required leech therapy, one flap was partially salvaged and three flaps were completely lost. Leech therapy was associated with higher total flap loss rates (75.0% vs. 42.1%) and longer length of stay (8.0 ± 3.6 days vs. 6.5 ± 2.1 days) when compared to non-leeched flaps. These differences were not statistically significant (P = 0.32 and P = 0.43, respectively). CONCLUSIONS: In patients with surgically uncorrectable venous congestion after free flap breast reconstruction, total flap loss is common despite leech therapy. When venous congestion cannot be corrected, total flap removal may be a better option than attempted salvage with leech therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsFemaleFree Tissue FlapsHumansHyperemiaLeechingMammaplastyMiddle AgedPostoperative ComplicationsRetrospective StudiesSalvage Therapy

Resumen

Among 23 patients with post-operative venous congestion after free flap breast reconstruction, 4 had surgically uncorrectable congestion requiring leech therapy. Total flap loss occurred in 75% of leeched flaps, suggesting that flap removal may sometimes be preferable to salvage attempts.

Por qué esto importa para la hirudoterapia

This study reviewed institutional experience with medicinal leech therapy for surgically uncorrectable venous congestion following free flap breast reconstruction, identifying 4 of 23 patients with postoperative venous congestion who required leeching after surgical correction failed. Among leech-treated patients, one flap was partially salvaged and three were completely lost (75% total flap loss), with higher transfusion requirements and lower hemoglobin nadirs compared to non-leeched patients, though differences were not statistically significant. For ASH, this is directly relevant as it examines real-world outcomes of hirudotherapy in a specific surgical complication. The authors conclude that total flap loss is common despite leech therapy and suggest flap removal may be preferable when venous congestion is uncorrectable. The caveat is the very small sample (n=4 leech-treated patients) and lack of statistical significance, limiting any conclusions about leech therapy efficacy.

Citación

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction.

Pannucci CJ et al. · Microsurgery, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.